Volume | 194,533 |
|
|||||
News | - | ||||||
Day High | 4.85 | Low High |
|||||
Day Low | 4.65 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
VistaGen Therapeutics Inc | VTGN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
4.71 | 4.65 | 4.85 | 4.75 | 4.70 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
1,388 | 194,533 | US$ 4.75 | US$ 923,388 | - | 1.62 - 24.71 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
15:00:06 | formt | 108 | US$ 4.75 | USD |
VistaGen Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
128.64M | 27.03M | - | -227k | -59.25M | -2.19 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
VistaGen Therapeutics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VTGN Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.68 | 5.00 | 4.55 | 4.76 | 160,685 | 0.07 | 1.50% |
1 Month | 5.40 | 5.74 | 4.53 | 5.09 | 243,260 | -0.65 | -12.04% |
3 Months | 4.77 | 5.74 | 3.9114 | 4.86 | 261,053 | -0.02 | -0.42% |
6 Months | 3.09 | 5.86 | 2.4501 | 4.45 | 404,306 | 1.66 | 53.72% |
1 Year | 4.137 | 24.71 | 1.62 | 6.12 | 1,213,331 | 0.613 | 14.82% |
3 Years | 63.00 | 106.50 | 1.62 | 16.71 | 3,378,912 | -58.25 | -92.46% |
5 Years | 31.50 | 106.50 | 1.62 | 21.79 | 2,544,602 | -26.75 | -84.92% |
VistaGen Therapeutics Description
Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Vistagen's pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. Its portfolio includes PH94B, a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia. PH10, an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression. |